Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, ...

Please provide your email address to receive an email when new articles are posted on . Sotyktu significantly improved skin and joint symptoms of psoriatic arthritis and reduced patient-reported ...

(RTTNews) - Sanofi Winthrop Industrie announced that positive results from the HERCULES phase 3 study, published in The New England Journal of Medicine (NEJM), showed that tolebrutinib delayed ...

Braintree ® intends to submit results from the TRIUMpH Phase 3 studies to a high impact, peer reviewed journal along with presentation of this data at a leading gastroenterology conference in the ...

A phase 3 trial in metastatic melanoma is ongoing, with a Biologics License Application expected by year-end. The vaccines offer a novel approach by targeting the entire tumor environment ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

PRINCETON, N.J., April 14, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients ...

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...

(RTTNews) - Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009 ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and consider other paths to market, The Wall Street Journal reports. Women’s ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Ironwood Pharmaceuticals shares sank after the company said it needs to conduct a confirmatory phase 3 trial of proposed short-bowel treatment apraglutide. The stock hit a 52-week low in mid ...